HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Myung-Ju Ahn Selected Research

Thymic epithelial tumor

1/2020Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment.
1/2019Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial.
1/2017Antineutrophil Cytoplasmic Antibody-Associated Rapid Progressive Glomerulonephritis after Pembrolizumab Treatment in Thymic Epithelial Tumor: A Case Report.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Myung-Ju Ahn Research Topics

Disease

240Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
04/2024 - 12/2005
158Neoplasms (Cancer)
05/2024 - 04/2002
44Lung Neoplasms (Lung Cancer)
02/2024 - 09/2010
41Neoplasm Metastasis (Metastasis)
12/2023 - 04/2004
35Disease Progression
03/2024 - 09/2009
19Adenocarcinoma
11/2021 - 01/2009
18Adenocarcinoma of Lung
10/2023 - 02/2010
17Squamous Cell Carcinoma of Head and Neck
03/2024 - 08/2011
15Small Cell Lung Carcinoma (Small Cell Lung Cancer)
03/2024 - 12/2009
13Brain Neoplasms (Brain Tumor)
04/2023 - 05/2010
12Esophageal Squamous Cell Carcinoma
05/2024 - 08/2008
12Fatigue
02/2024 - 06/2013
10Carcinoma (Carcinomatosis)
10/2023 - 04/2002
8Diarrhea
02/2024 - 12/2012
8Exanthema (Rash)
04/2019 - 01/2010
7Stroke (Strokes)
03/2024 - 01/2012
7Nausea
02/2024 - 08/2015
7Interstitial Lung Diseases (Interstitial Lung Disease)
01/2021 - 02/2010
6Adenoid Cystic Carcinoma (Cylindroma)
04/2024 - 05/2012
6Neutropenia
03/2024 - 08/2013
6Colorectal Neoplasms (Colorectal Cancer)
12/2017 - 04/2004
5Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/2019 - 09/2010
4Anemia
03/2024 - 04/2015
4Melanoma (Melanoma, Malignant)
03/2024 - 10/2017
4Vomiting
02/2024 - 01/2017
4Head and Neck Neoplasms (Head and Neck Cancer)
10/2023 - 02/2016
4Pneumonia (Pneumonitis)
10/2023 - 04/2015
4Nasopharyngeal Carcinoma
01/2023 - 06/2015
4Breast Neoplasms (Breast Cancer)
10/2017 - 02/2004
4Nasopharyngeal Neoplasms (Cancer of the Nasopharynx)
02/2016 - 07/2011
4Sarcoma (Soft Tissue Sarcoma)
01/2016 - 02/2014
4Stomach Neoplasms (Stomach Cancer)
09/2006 - 02/2004
3Hemorrhage
03/2024 - 12/2016
3Thrombosis (Thrombus)
05/2023 - 12/2016
3Salivary Gland Neoplasms (Salivary Gland Cancer)
07/2022 - 10/2014
3Leukemia
01/2022 - 09/2002

Drug/Important Bio-Agent (IBA)

80ErbB Receptors (EGF Receptor)IBA
02/2024 - 07/2009
73Tyrosine Kinase InhibitorsIBA
04/2024 - 07/2009
37Immune Checkpoint InhibitorsIBA
03/2024 - 01/2016
31Biomarkers (Surrogate Marker)IBA
03/2024 - 07/2009
31Gefitinib (Iressa)FDA Link
12/2023 - 01/2009
31PlatinumIBA
11/2023 - 01/2009
28Pemetrexed (MTA)FDA Link
01/2020 - 01/2009
27osimertinibIBA
10/2023 - 04/2015
27Cisplatin (Platino)FDA LinkGeneric
01/2023 - 02/2005
22CrizotinibIBA
12/2023 - 05/2012
19pembrolizumabIBA
04/2024 - 05/2015
17Erlotinib Hydrochloride (CP 358,774)FDA Link
04/2023 - 06/2008
15Proteins (Proteins, Gene)FDA Link
12/2023 - 02/2005
15Anaplastic Lymphoma KinaseIBA
05/2021 - 05/2012
13durvalumabIBA
03/2024 - 04/2017
13Docetaxel (Taxotere)FDA Link
10/2023 - 12/2005
11LigandsIBA
04/2024 - 01/2016
11Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link
01/2024 - 09/2009
11brigatinibIBA
12/2023 - 08/2017
11Phosphotransferases (Kinase)IBA
10/2023 - 03/2014
10DNA (Deoxyribonucleic Acid)IBA
02/2024 - 08/2015
10Bevacizumab (Avastin)FDA Link
10/2023 - 11/2010
9lazertinibIBA
02/2024 - 12/2019
9Monoclonal AntibodiesIBA
10/2023 - 02/2009
8fibrin fragment D (D-dimer)IBA
03/2024 - 01/2012
8AfatinibIBA
04/2023 - 07/2014
7Circulating Tumor DNAIBA
03/2024 - 01/2020
7Fluorouracil (Carac)FDA LinkGeneric
01/2023 - 06/2004
6tremelimumabIBA
03/2024 - 01/2020
6B7-H1 AntigenIBA
12/2023 - 01/2019
6entrectinibIBA
05/2022 - 01/2020
6NivolumabIBA
01/2022 - 01/2019
6Thymidylate SynthaseIBA
01/2019 - 08/2005
6GemcitabineFDA Link
10/2017 - 06/2011
5atezolizumabIBA
05/2024 - 01/2019
5Paclitaxel (Taxol)FDA LinkGeneric
10/2017 - 06/2004
4Alanine Transaminase (SGPT)IBA
03/2024 - 04/2016
4Cell-Free Nucleic AcidsIBA
02/2024 - 02/2016
4alectinibIBA
12/2023 - 05/2021
4ceritinibIBA
12/2022 - 01/2016
4ParaffinIBA
01/2020 - 06/2004
4Carboplatin (JM8)FDA LinkGeneric
10/2017 - 04/2014
4dacomitinibIBA
10/2017 - 10/2014
4Oxaliplatin (Eloxatin)FDA LinkGeneric
07/2017 - 08/2005
4Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
09/2006 - 04/2002
3Aspartate Aminotransferases (Aspartate Transaminase)IBA
03/2024 - 12/2016
3binimetinibIBA
02/2024 - 03/2022
3encorafenibIBA
02/2024 - 03/2022
3SteroidsIBA
12/2023 - 01/2020
3pralsetinibIBA
11/2023 - 12/2021
3vandetanib (ZD6474)IBA
11/2023 - 12/2013
3Cetuximab (Erbitux)FDA Link
11/2023 - 12/2019
3nintedanibIBA
07/2023 - 12/2016
3tyrosine receptor (receptor, tyrosine)IBA
07/2023 - 10/2015
3Indicators and Reagents (Reagents)IBA
08/2021 - 11/2016

Therapy/Procedure

118Therapeutics
04/2024 - 10/2003
92Drug Therapy (Chemotherapy)
01/2024 - 12/2002
26Chemoradiotherapy
03/2024 - 07/2011
21Radiotherapy
04/2023 - 09/2009
16Immunotherapy
11/2023 - 10/2009
9Neoadjuvant Therapy
03/2023 - 04/2012
7Combination Drug Therapy (Combination Chemotherapy)
02/2023 - 06/2004
5Aftercare (After-Treatment)
12/2020 - 02/2013
3Drug Tapering
11/2023 - 01/2019